Skip to main content
. 2017 Aug 6;8(40):66925–66939. doi: 10.18632/oncotarget.19963

Figure 10. Ov-Mito-Signature 2 predicts patient outcome in ovarian cancer patients.

Figure 10

Note that high levels of Ov-Mito-Signature 2 (NDUFA3/UQCRFS1) effectively predicts overall survival (OS), progression-free survival (PFS) and post-progression survival (PPS). OS and PFS are shown in panel A. PPS is shown in panel B.